Exscientia plc (NASDAQ:EXAI - Get Free Report)'s share price gapped down prior to trading on Monday . The stock had previously closed at $5.21, but opened at $5.09. Exscientia shares last traded at $5.11, with a volume of 18,248 shares changing hands.
Analyst Upgrades and Downgrades
Several research firms have weighed in on EXAI. Barclays reissued an "equal weight" rating and set a $5.00 target price on shares of Exscientia in a research report on Tuesday, August 13th. TD Cowen restated a "hold" rating on shares of Exscientia in a research note on Friday, August 9th.
Get Our Latest Report on Exscientia
Exscientia Stock Down 2.3 %
The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $615.31 million, a price-to-earnings ratio of -3.87 and a beta of 0.84. The business's 50-day moving average is $5.14 and its 200-day moving average is $5.06.
Exscientia (NASDAQ:EXAI - Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.05). The company had revenue of $5.60 million during the quarter. Exscientia had a negative net margin of 620.99% and a negative return on equity of 37.56%. As a group, equities analysts predict that Exscientia plc will post -1.25 earnings per share for the current year.
Hedge Funds Weigh In On Exscientia
A number of large investors have recently bought and sold shares of the business. Novo Holdings A S purchased a new stake in shares of Exscientia in the second quarter valued at approximately $66,742,000. Bank of New York Mellon Corp increased its holdings in Exscientia by 108.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company's stock worth $1,981,000 after acquiring an additional 202,377 shares in the last quarter. Federated Hermes Inc. acquired a new position in Exscientia during the second quarter worth $115,000. Susquehanna Fundamental Investments LLC acquired a new position in Exscientia during the second quarter worth $256,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Exscientia in the second quarter valued at about $54,000. Institutional investors and hedge funds own 41.58% of the company's stock.
Exscientia Company Profile
(
Get Free Report)
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
Further Reading
Before you consider Exscientia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exscientia wasn't on the list.
While Exscientia currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
